

**Arbeitsgruppensitzung Autoimmunbullöse Dermatosen  
im Rahmen der ADF-Tagung Düsseldorf 2024**

**Donnerstag, den 7.3.2024 von 8:30 bis 12:30 Uhr**

Heinrich-Heine-Universität Düsseldorf, Universitätsstr. 1, 40225 Düsseldorf, Hörsaal 2B

**(10 Minuten pro Referat einschl. Diskussion in englischer Sprache!)**

**8:30 Begrüßung**, Michael Sticherling, Erlangen

**Epidermolysis bullosa acquisita (EBA)**

**8:40**

T Cell Receptor Repertoire Analysis During the Pathogenesis of the Autoimmune Skin Blistering Disease Epidermolysis Bullosa Acquisita **(P124)**

F. Bahreini, M. Niebuhr, K. Bieber, C. Hammers, J. Westermann, K. Kalies, Luebeck

**Bullous Pemphigoid**

**8:50**

Bullous pemphigoid induced by IgG targeting murine type XVII collagen non-NC15A extracellular domains is driven by Fc gamma receptor-mediated effector mechanisms and ameliorates with neonatal Fc receptor blockade. **(P123)**

M. Pigors, S. Patzelt, S. Khilchenko, S. Emtenani, K. Bieber, M. Kamaguchi, S. Goletz, L. Komorowski, C. Probst, K. Vanderheyden, B. Balbino, R. Ludwig, P. Verheesen, E. Schmidt, Luebeck, Ghent

**9:00**

Involvement of Alternative C5-Convertases in Inducing Skin Inflammation in Experimental Pemphigoid Diseases **(P129)**

S. Mousavi, M. Kamaguchi, K. Izumi, S. Draeger, L. Schmidt-Jiménez, A. Kasprick, S. Patzelt, S. Emtenani, M. Pigors, K. Bieber, E. Schmidt, R. Ludwig, Luebeck

**9:10**

Bullous pemphigoid induced by immune checkpoint inhibitors – an issue of relevance? **(P159)**

M. Sticherling, M. Brückner, R. Kramer, M. Erdmann, Erlangen

**9:20**

Gamma delta T cells boost blister formation during PD-1 immune checkpoint therapy in pemphigoid disease **(P165)**

J. Pruessmann, W. Pruessmann, C. Sadik, Luebeck

**9:30**

Gliptin-induced bullous pemphigoid: characterization of patient autoantibody profiles and direct effects on adaptive immune cells **(P163)**

L. Schmidt-Jiménez, D. Wortmann, M. Kamaguchi, S. Draeger, D. De Luca, S. Goletz, E. Schmidt, R. Ludwig, K. Kridin, K. Bieber, Luebeck, Barcelona, Nahariya, Safed

**9:40**

Importance of pre-clinical validation of pharmacological targets in pemphigoid diseases **(P160)**

S. Draeger, L. Schmidt-Jiménez, S. Staender, Y. Gupta, K. Kalies, R. Ludwig, K. Bieber, Luebeck, New York

**Pemphigus**

**9:50**

FasL enhances AK23-induced Acantholysis in a Caspase-dependent Manner in P. Vulgaris **(P024)**

M. Schmidt, M. Feoktistova, D. Panayotova-Dimitrova, A. Yazdi, Aachen

**10:00**

Transcriptome analysis defines combinatory pathway activity in keratinocytes necessary for split formation in pemphigus vulgaris **(P064)**

S. Guo, V. Hartmann, U. Radine, I. Burmester, W. Hariton, S. Rahimi, C. Hammers, R. Ludwig, E. Mueller, H. Busch, J. Hundt, Luebeck, Bern

**10:10**

Characterization of pemphigus patients by plasma-derived extracellular vesicles **(P162)**

A.Jung, K. Laakmann, C. Zimmer, D. Didona, A. Mesas Fernandez, F. Solimani, C. Moebs, Marburg, Berlin

**10:20**

Establishing a human 3D skin model for pemphigus **(P166)**

E. Janusch, Luebeck

**10:30**

Quality-controlled characterization of an EC5 specific monoclonal antibody against Desmoglein 3 as a standardized tool for preclinical pemphigus analysis **(P122)**

R. Eming, E. Mueller, A. Zakrzewicz, U. Linne, R. Tikkanen, C. Hudemann, Marburg, Koblenz, Bern, Giessen

**10:40**

Desmoglein 3 peptides-conjugated nanoparticles as a novel tool for tolerance induction in a preclinical pemphigus vulgaris (PV) mouse model **(P111)**

C. Hudemann, D. Krzikalla, B. Metzler, R. Digigow, R. Eming, M. Hertl, S. Fleischer, H. Garn, Marburg, Hamburg, Koblenz

**10:50**

Profiling of circulating Dsg3 peptide-reactive T helper cells in pemphigus vulgaris patients"

J. Hinterseher, Marburg

**11:00-11:20 Pause****11:20**

Safety, tolerability and pharmacokinetics of TPM203, a tolerizing Topas particle mixture in pemphigus vulgaris: preliminary results from a phase 1, first in man study **(P152)**

D. Didona, K. Volkmann, J. Hinterseher, C. Moebs, R. Pollmann, A. Polakova, W. Pfuetzner, T. Cunha, F. Schauer, M. Hahn, K. Meier, N. Magnolo, M. Sticherling, S. Fleischer, M. Hertl, Marburg, Freiburg, Tuebingen, Berlin, Muenster, Erlangen, Hamburg

**Autoimmune blistering dermatoses****11:30**

Lesion localization in autoimmune blistering dermatoses is independent of site-specific antigen expression **(P083)**

T. Rastegar Lari, L. Macias, O. Dikmen, I. Weyers, I. Koenig, N. van Beek, E. Schmidt, S. Emtenani, Luebeck

**11:40**

Testing the effect of kinase inhibitors in the human skin organ culture model **(P095)**

C. Walczyk, C. Hammers, T. Lange, R. Ludwig, J. Hundt, Luebeck, Kiel

**11:50**

The distribution of putative skin autoantigens is not limited to a specific type of inflammatory skin disease. **(P115)**

Y. Koeseoglu, T. Biedermann, S. Eyerich, N. Garzorz-Stark, M. Jargosch; Munich, Stockholm

**12:00**

JAK/STAT-inhibition for bullous pemphigoid

F. Solimani, Berlin

**12:10 -12:30 Wahl des AG-Sprechers, Verschiedenes, Projekte**